Montefiore Einstein Center for Cancer Care | Strategic Alliance Partners

January 18, 2021

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

December 15, 2020

Balazs Halmos, MD discusses the year 2021 and how it will encompass a bigger focus on neoadjuvant and adjuvant trials, more novel molecular compounds for more select subgroups, and a migration of circulating tumor DNA into a more minimal residual disease–based setting.

November 10, 2020

Haiying Cheng, MD, PhD highlights new data from key clinical trials in extensive-stage small cell lung cancer.

November 05, 2020

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

November 04, 2020

Ira Braunschweig, MD, discusses factors to consider when selecting between autologous stem cell transplant, allogeneic stem cell transplant, and CAR T-cell therapy in diffuse large B-cell lymphoma.

November 02, 2020

Balazs Halmos, MD, MS, highlights the significance of the ADAURA trial in EGFR-positive NSCLC, questions raised by these data, and other efforts being made in the adjuvant setting.